Literature DB >> 12916874

Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.

Quan Chen1, Subrata Ray, Mohamad A Hussein, Gordan Srkalovic, Alexandru Almasan.   

Abstract

Apo2 Ligand or Tumour Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) is a member of the TNF gene superfamily that selectively induces apoptosis in tumor cells of diverse origins through engagement of death receptors. We have recently demonstrated that Type I interferons (IFN-alpha and beta) induce apoptosis in multiple myeloma (MM) cell lines and in plasma cells from MM patients. Moreover, Apo2L selectively induces apoptosis of patient MM tumor cells while sparing non-malignant cells. Apo2L induction is one of the earliest events following IFN administration in these cells. IFNs activate Caspases and the mitochondrial-dependent apoptotic pathway mediated by Apo2L production. Cell death induced by IFNs and Apo2L can be blocked by a dominant-negative Apo2L receptor, DRS, and is regulated by members of the Bcl-2 family of proteins. This review is focused on the apoptotic signaling pathways regulated by Apo2L and Bcl-2-family proteins and summarizes what is known about their clinical role.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12916874      PMCID: PMC1199086          DOI: 10.1080/1042819031000068052

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  66 in total

Review 1.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily.

Authors:  Avi Ashkenazi
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 2.  The Bcl2 family: regulators of the cellular life-or-death switch.

Authors:  Suzanne Cory; Jerry M Adams
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

3.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

Review 4.  Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells.

Authors:  Chiharu Kawamura; Masahiro Kizaki; Yasuo Ikeda
Journal:  Leuk Lymphoma       Date:  2002-03

5.  Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

6.  Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL.

Authors:  M M Schwarze; R G Hawley
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

7.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

Authors:  Sophie Derenne; Brett Monia; Nicholas M Dean; Jennifer K Taylor; Marie-Josée Rapp; Jean-Luc Harousseau; Régis Bataille; Martine Amiot
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

8.  Expression of Bcl-2 protein and Bcl-2 mRNA in normal and neoplastic lymphoid tissues.

Authors:  T Akagi; E Kondo; T Yoshino
Journal:  Leuk Lymphoma       Date:  1994-03

9.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells.

Authors:  M Pettersson; H Jernberg-Wiklund; L G Larsson; C Sundström; I Givol; Y Tsujimoto; K Nilsson
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

10.  Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells.

Authors:  M J Robertson; T J Manley; G Pichert; C Cameron; K J Cochran; H Levine; J Ritz
Journal:  Leuk Lymphoma       Date:  1995-03
View more
  7 in total

1.  The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.

Authors:  Shuhong Zhang; Attaya Suvannasankha; Colin D Crean; Valerie L White; Ching-Shih Chen; Sherif S Farag
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

Review 2.  Apoptosis of multiple myeloma.

Authors:  Marcela Oancea; Aruna Mani; Mohamad A Hussein; Alexandru Almasan
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

3.  Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.

Authors:  Jinxiang Fu; Panjun Wang; Xiaohui Zhang; Suguang Ju; Jie Li; Binzhou Li; Sun Yu; Jianhua Zhang; Xueguang Zhang
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

4.  Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats.

Authors:  Mohamed M Hafez; Naif O Al-Harbi; Ali Rashed Al-Hoshani; Khaled A Al-Hosaini; Shakir D Al Shrari; Salim S Al Rejaie; Mohamed M Sayed-Ahmed; Othman A Al-Shabanah
Journal:  Biol Res       Date:  2015-06-11       Impact factor: 5.612

5.  DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.

Authors:  Baoyue Ding; Wei Zhang; Xin Wu; Jeffrey Wang; Chen Xie; Xuan Huang; Shuyu Zhan; Yongxia Zheng; Yueyan Huang; Ningyin Xu; Xueying Ding; Shen Gao
Journal:  Oncotarget       Date:  2016-08-30

6.  Differential Effects of IFN-β on the Survival and Growth of Human Vascular Smooth Muscle and Endothelial Cells.

Authors:  Emiko Sano; Shinya Tashiro; Kouhei Tsumoto; Takuya Ueda
Journal:  Biores Open Access       Date:  2015-01-01

7.  Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells.

Authors:  Wenwen Zhou; Huying Chen; Xiuli Hong; Xiaoqing Niu; Quanyi Lu
Journal:  Oncol Lett       Date:  2014-08-26       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.